Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

March 29, 2019

Primary Completion Date

January 2, 2020

Study Completion Date

January 2, 2020

Conditions
Relapsing Multiple Sclerosis
Interventions
DRUG

SAR442168

Pharmaceutical form: Film coated tablet; Route of administration: Oral

DRUG

Placebo

Pharmaceutical form: Film coated tablet; Route of administration: Oral

DRUG

Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI)

Pharmaceutical form: Solution for injection; Route of administration: Intravenous

Trial Locations (48)

10002

Investigational Site Number 8040007, Zhytomyr

11315

Investigational Site Number 2330001, Tallinn

12808

Investigational Site Number 2030001, Prague

15006

Investigational Site Number 2030002, Praha 5 - Motol

17190

Investigational Site Number 7240005, Salt

21005

Investigational Site Number 8040003, Vinnytsia

28007

Investigational Site Number 7240001, Madrid

30120

Investigational Site Number 7240004, Murcia

31059

Investigational Site Number 2500003, Toulouse

31406

Investigational Site Number 8400007, Savannah

32761

Investigational Site Number 8400002, Maitland

33351

Investigational Site Number 8400004, Sunrise

33612

Investigational Site Number 8400009, Tampa

35058

Investigational Site Number 8400005, Cullman

37922

Investigational Site Number 8400003, Knoxville

41071

Investigational Site Number 7240003, Seville

43081

Investigational Site Number 8400006, Westerville

44093

Investigational Site Number 2500001, Nantes

45417

Investigational Site Number 8400008, Dayton

48903

Investigational Site Number 7240006, Barakaldo

49005

Investigational Site Number 8040005, Dnipro

50005

Investigational Site Number 2030004, Hradec Králové

53203

Investigational Site Number 2030006, Pardubice

54035

Investigational Site Number 2500004, Nancy

58018

Investigational Site Number 8040002, Chernivtsi

58633

Investigational Site Number 2030003, Jihlava

60062

Investigational Site Number 8400001, Northbrook

62500

Investigational Site Number 2030007, Brno

65025

Investigational Site Number 8040009, Odesa

67098

Investigational Site Number 2500002, Strasbourg

70852

Investigational Site Number 2030005, Ostrava - Poruba

79010

Investigational Site Number 8040001, Lviv

79013

Investigational Site Number 8040006, Lviv

82606

Investigational Site Number 7030001, Bratislava

125367

Investigational Site Number 6430003, Moscow

127015

Investigational Site Number 6430002, Moscow

194044

Investigational Site Number 6430005, Saint Petersburg

197022

Investigational Site Number 6430004, Saint Petersburg

197110

Investigational Site Number 6430001, Saint Petersburg

420021

Investigational Site Number 6430006, Kazan'

625000

Investigational Site Number 6430007, Tyumen

J8Y 1W2

Investigational Site Number 1240002, Gatineau

J4V 2J2

Investigational Site Number 1240001, Greenfield Park

V6T 2B5

Investigational Site Number 1240003, Vancouver

1081 HV

Investigational Site Number 5280001, Amsterdam

6162 BG

Investigational Site Number 5280002, Sittard-Geleen

03659

Investigational Site Number 7030002, Martin

08035

Investigational Site Number 7240002, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT03889639 - Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis | Biotech Hunter | Biotech Hunter